Key result
Each mg equivalent of bisoprolol and ramipril is linked to ~5% lower mortality in HFmrEF.
Why the study?
Current guidelines recommend that disease-modifying pharmacological therapies may be considered for patients with HFmrEF, prompting this evaluation of characteristics, outcomes, therapy provision, and dose-related mortality associations.
Do pharmacological therapies such as beta-blockers and renin-angiotensin inhibitors reduce all-cause mortality in patients with HFmrEF?
Observational (n=2,388)
Yes
Do pharmacological therapies such as beta-blockers and renin-angiotensin inhibitors reduce all-cause mortality in patients with HFmrEF?
Effect estimate: HR 0.95 (95% CI 0.91-1.00)
p-value: p=0.047
Higher doses of beta-blockers and renin-angiotensin inhibitors are associated with lower mortality risk in patients with HFmrEF, similar to the benefits seen in HFrEF.
No takes yet. Share an insight, caveat, or question.
Supports dose optimization of beta-blockers and ACEIs in HFmrEF; hypothesis-generating and leaves open randomized confirmation.
Straw et al. (2022) conducted an observational in Heart failure with mildly reduced ejection fraction (HFmrEF) (n=2,388). Guideline-directed medical therapy (beta-blockers and ACEi/ARB) vs. No therapy or lower doses was evaluated on All-cause mortality (per mg equivalent of bisoprolol) (HR 0.95, 95% CI 0.91-1.00, p=0.047). In patients with heart failure with mildly reduced ejection fraction, each mg equivalent dose of bisoprolol (HR 0.95) and ramipril (HR 0.95) was associated with incremental reductions in all-cause mortality risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: